Please provide your email address to receive an email when new articles are posted on . CHICAGO — In high-risk patients with implantable cardioverter defibrillators, ranolazine did not reduce the ...
The results of TERISA, a randomized, double-blind trial in which the effect of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina was examined, were reported at the ACC ...
Ranolazine is an antianginal drug and a class V antiarrhythmic drug that is mainly used for the treatment of chronic angina. Ranolazine is also used off-label to treat certain arrhythmias, including ...
SAN FRANCISCO — The first prospective international randomized controlled study focusing specifically on angina in patients with diabetes has shown that ranolazine (Ranexa, Gilead Sciences) is an ...
Palo Alto, California Fears over QT prolongation are mounting for a range of already approved drugs, as well as for agents still in the pipeline. This past week, ranolazine, CV Therapeutics' new ...
Pulmonary Circulation, Vol. 5, No. 4 (December 2015), pp. 691-700 (10 pages) AbstractPulmonary arterial hypertension (PAH) causes right ventricular ischemia, dysfunction, and failure. PAH patients may ...
Detection of EGFR mutations in NSCLC patients in clinical practice: Comparison between cobas and Scorpion ARMS method. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This ...
On page 453, information summarizing the efficacy of ranolazine in the ERICA trial was reported incorrectly. The correct information is: Statistically significant decreases in angina attack frequency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback